A Study of Sigvotatug Vedotin in Advanced Solid Tumors
for Carcinoma, Non-Small Cell Lung
104 locations incl. Anchorage
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Sex: All·Age: 18+
Code: NCT04389632·Phase 1·Recruiting·Listed May 2020
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
Clinical research site in New Lenox, Illinois
Part of University of Chicago
As of July 2026, 2 paid clinical trials are recruiting at University of Chicago Comprehensive Cancer Center at Silver Cross Hospital in New Lenox, Illinois. Active studies at this site cover conditions such as Carcinoma, Non-Small Cell Lung, Cutaneous Squamous Cell Cancer and Esophageal Adenocarcinoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at University of Chicago Comprehensive Cancer Center at Silver Cross Hospital (2)
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
for Urothelial Carcinoma
144 locations incl. Gilbert
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Sex: All·Age: 18+
Code: NCT04879329·Phase 2·Recruiting·Listed May 2021
More research sites in New Lenox
- UC Comprehensive Cancer Center at Silver Cross (40 trials)
- Hope and Healing Cancer Services (3 trials)
- Hope and Healing Clinical Research (2 trials)
- Advanced Urology Associates (1 trial)
- Hope and Healing Clinical Research LLC New Lenox- Research Department (1 trial)
- Silver Cross Surgery Center (1 trial)
- UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital (1 trial)
- University of Chicago (1 trial)
- University of Chicago Comprehensive Cancer Center at Silver Cross (1 trial)
Explore more
Paid clinical trials in New Lenox, IL · Illinois clinical trials